Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

496 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multifaceted approach to determine the antagonist molecular mechanism and interaction of ibodutant ([1-(2-phenyl-1R-[[1-(tetrahydropyran-4-ylmethyl)-piperidin-4-ylmethyl]-carbamoyl]-ethylcarbamoyl)-cyclopentyl]-amide) at the human tachykinin NK2 receptor.
Meini S, Bellucci F, Catalani C, Cucchi P, Giolitti A, Santicioli P, Giuliani S. Meini S, et al. Among authors: giuliani s. J Pharmacol Exp Ther. 2009 May;329(2):486-95. doi: 10.1124/jpet.108.150201. Epub 2009 Feb 13. J Pharmacol Exp Ther. 2009. PMID: 19218528
Pharmacological profile of the novel mammalian tachykinin, hemokinin 1.
Bellucci F, Carini F, Catalani C, Cucchi P, Lecci A, Meini S, Patacchini R, Quartara L, Ricci R, Tramontana M, Giuliani S, Maggi CA. Bellucci F, et al. Among authors: giuliani s. Br J Pharmacol. 2002 Jan;135(1):266-74. doi: 10.1038/sj.bjp.0704443. Br J Pharmacol. 2002. PMID: 11786503 Free PMC article.
MEN16132, a novel potent and selective nonpeptide antagonist for the human bradykinin B2 receptor. In vitro pharmacology and molecular characterization.
Cucchi P, Meini S, Bressan A, Catalani C, Bellucci F, Santicioli P, Lecci A, Faiella A, Rotondaro L, Giuliani S, Giolitti A, Quartara L, Maggi CA. Cucchi P, et al. Among authors: giuliani s. Eur J Pharmacol. 2005 Dec 28;528(1-3):7-16. doi: 10.1016/j.ejphar.2005.10.014. Epub 2005 Dec 1. Eur J Pharmacol. 2005. PMID: 16324696
MEN15596, a novel nonpeptide tachykinin NK2 receptor antagonist.
Cialdai C, Tramontana M, Patacchini R, Lecci A, Catalani C, Catalioto RM, Meini S, Valenti C, Altamura M, Giuliani S, Maggi CA. Cialdai C, et al. Among authors: giuliani s. Eur J Pharmacol. 2006 Nov 7;549(1-3):140-8. doi: 10.1016/j.ejphar.2006.08.021. Epub 2006 Aug 26. Eur J Pharmacol. 2006. PMID: 16979621
Pharmacological characterization of the bradykinin B2 receptor antagonist MEN16132 in rat in vitro bioassays.
Meini S, Cucchi P, Catalani C, Bellucci F, Giuliani S, Santicioli P, Maggi CA. Meini S, et al. Among authors: giuliani s. Eur J Pharmacol. 2009 Aug 1;615(1-3):10-6. doi: 10.1016/j.ejphar.2009.04.057. Epub 2009 May 13. Eur J Pharmacol. 2009. PMID: 19445925
In these assays MEN16132 (pK(B): 9.7 both in uterus and bladder) was about 10-fold more potent than icatibant [pK(B): 8.8 in uterus, and pK(B) 8.0 in urinary bladder, as from Meini, S., Patacchini, R., Giuliani, S., Lazzeri, M., Turini, D., Maggi, C.A., Lecci …
In these assays MEN16132 (pK(B): 9.7 both in uterus and bladder) was about 10-fold more potent than icatibant [pK(B): 8.8 in uterus, and pK( …
496 results